|
NMRR-09-200-3744
|
A Long Term, Open-Label Follow Up Study Of Tasocitinib (CP-690,550) A Moderately Selective Janus-Kinase-3 Inhibitor, For Treatment Of Rheumatoid Arthritis |
| NMRR-10-1203-7871 |
A randomized, double-blind, parallel-group study of safety and the effect on clinical outcome of tocilizumab SC versus placebo SC in combination with traditional disease modifying anti-rheumatic drugs (DMARDs) in patients with moderate to severe active rheumatoid arthritis |
| NMRR-10-323-5594 |
A randomized, double blind, multi-centric, placebo controlled, phase II study assessing the safety and efficacy of intraarticular ex-vivo cultured adult allogenic mesenchymal stem cells in patients with Osteoarthritis (OA) of knee. |
| NMRR-10-396-5377 |
A randomised, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution delivered by the Respimat® Inhaler with Tiotropium inhalation capsules 18 µg delivered by the HandiHaler®. |
| NMRR-10-706-6055 |
A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in type 2 diabetes mellitus patients with increased cardiovascular risk. |
| NMRR-10-887-7320 |
BH21260B: A randomized, controlled, open-label, multi-centre, parallel-group study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on renal replacement therapy under treatment with MIRCERA® or reference ESAs. |
| NMRR-11-398-9366 |
A Long-Term Multicenter, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole (OPC 14597) as Maintenance Treatment in Adolescent Patients with Schizophrenia |
| NMRR-11-642-9707 |
An open, national, multicentre study over 6 weeks of treatment with the objective of evaluating the efficacy and safety of Valdoxan in the treatment of major depressive disorder in an out patient setting. |
| NMRR-10-1223-7478 |
EXenatide Study of Cardiovascular Event Lowering Trial (EXSCEL) - A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus |
| NMRR-13-1371-18609 |
A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal TRANSplantation- Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM) |
| NMRR-11-373-9350 |
A clinical outcomes study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) in comparison with etanercept (ETA) on the rate of cardiovascular events in patients with moderate to severe rheumatoid arthritis (RA). |
| NMRR-11-986-10501 |
The Study of Heart and Renal Protection - Extended Review - SHARPER |
| NMRR-10-1050-7598 |
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to Methotrexate Therapy. (Vaccine Addendum) |
| NMRR-10-965-7458 |
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to Methotrexate Therapy |
| NMRR-10-971-7459 |
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) with or without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy |
| NMRR-10-983-7456 |
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) |
| NMRR-10-1193-5556 |
An observational study of Rheumatoid arthritis patients on adalimumab to Evaluate quality of LIfe Variables, Effects on work productivity and functional outcomes in Malaysia |
| NMRR-11-117-8165 |
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations and Change in Lung Function in Patients (12-75 Years of Age) With Eosinophilic Asthma |
| NMRR-12-36-10802 |
A multicenter, double-masked, randomized, parallel assignment, study to determine the therapeutic equivalence of generic brinzolamide 1% ophthalmic suspension manufactured by InnoPharma Inc. with respect to AzoptTM (brinzolamide 1% ophthalmic suspension) in patients with primary open-angle glaucoma or ocular hypertension |
| NMRR-11-1010-10697 |
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects |
| NMRR-11-797-10330 |
SAS115359, a Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects with Asthma |
| NMRR-12-581-12838 |
A randomized, double-blind, 12-week treatment, parallelgroup study to evaluate the efficacy and safety of QMF149 (150 mcg /160 mcg o.d.) compared with salmeterol xinafoate/fluticasone propionate (50 mcg/500 mcg b.i.d.) in patients with chronic obstructive pulmonary disease |
| NMRR-12-1034-13734 |
Efficacy, safety and tolerability of amoxicillin + clavulanic acid (875mg/125mg) two times a day compared to clindamycin (150mg) four times a day for 5-7 days in treatment of acute odontogenic infection with or without abscess |
| NMRR-12-423-12180 |
Prevalence Study Of Gastrointestinal Risk Factors In Patients With Osteoarthritis, Rheumatoid Arthritis And Ankylosing Spondylitis Receiving Treatment With Non-Steroidal Antiinflammatory Drugs: Rational Study |
| NMRR-12-867-13138 |
A multicenter open-label study to evaluate the safety and efficacy of PEG-Intron TM versus PEGASYS TM in subjects with HBeAg positive chronic hepatits B and HBeAg negative chronic hepatitis B |
| NMRR-13-478-16374 |
A Phase 3 Clinical Trial to Study Short Duration Versus Standard Response-Guided Therapy with MK-3034 (SCH 503034)/Boceprevir Combined with PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Subjects with Chronic HCV Genotype 1 in Asia |
| NMRR-12-181-10976 |
A Multicenter, Randomised, Double-blind, Placebo-controlled Trial to Determine the Efficacy and Safety of Hepar-P capsule for the Treatment of Nan-Alcoholic Fatty Liver Disease (NAFLD) |
| NMRR-13-781-15947 |
A 24-month , phase IV, randomised double masked multi-centre study of ranibizumab monotherapy or ranibizumab in combination with vertepofin photodynamic therapy on visual outcome in patients with symtomatic macular polypoidal choroidal vasculopathy |
| NMRR-13-486-16638 |
A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy |
| NMRR-13-782-16912 |
A multi center, open label, randomized, two-treatment, single dose, crossover, bioequivalence study to compare the pharmacokinetics of marketed product TobraDex® (Tobramycin and Dexamethasone Ophthalmic ointment) to an experimental ophthalmic sterile ointment containing tobramycin 0.3% and dexamethasone 0.1% w/w in aqueous humor in patients undergoing indicated cataract surgery |
| NMRR-13-528-16604 |
A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS) |
| NMRR-13-59-14824 |
A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease. |
| NMRR-13-1520-18183 |
Phase 3B/4 Randomized Safety Endpoint Study of 2 doses of Tofacitinib in Comparison to a Tumor Necrosis Factor (TNF) Inhibitor in Subjects with Rheumatoid Arthritis |
| NMRR-13-23-14847 |
A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib Versus Sorafenib in Unresectable HCC Subjects |
| NMRR-12-1014-11876 |
Study to observe the effectiveness and safety of ranibizumab through individualized patient treatment and associated outcomes |
| NMRR-12-1102-13587 |
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the ocurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome |
| NMRR-14-1370-23056 |
A Multiple-Center, Randomized, Partially Double-Blind, Placebo-Controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Antiviral Effects Of 12-Week Treatment With Ro6864018 In Virologically Suppressed Entecavir Treated Patients With Hepatitis B Virus Infection |
| NMRR-14-699-21604 |
An International Multicenter Prospective Observational Study to Evaluate the Epidemiology, HumAnistic and Economic Outcomes of Treatment for ChronIc Hepatitis C Virus (HCV) |
| NMRR-13-781-15947 |
A 24 month, phase IV, randomized, double masked, multi-center study of ranibizumab monotherapy or ranibizumab in combination with verteporfin photodynamic therapy on visual outcome in patients with symptomatic macular polypoidal choroidal vasculopathy |
| NMRR-14-185-20068 |
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects who have Failed Prior Treatment with Pegylated Interferon and Ribavirin (P/R) with Chronic HCV GT1, GT4, GT5, and GT6 Infection |
| NMRR-14-1706-23078 |
A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial |
| NMRR-14-1288-23091 |
A Phase IIB-III, open-label, randomized, comparative study to assess the efficacy of ABX203 to maintain control of Hepatitis B disease after cessation of treatment with nucleos(t)ide analogs in adult HBeAg negative patients with chronic Hepatitis B in the Asia Pacific region |
| NMRR-15-714-25491 |
Budget Impact Analysis (BIA) of VIEKIRAX + EXVIERA and current standard of treatment for the Treatment of Hepatitis C in Malaysia |
| NMRR-13-96-15078 |
DiabCare Asia 2012 - Malaysia. A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of patients with type 2 diabetes in Malaysia. Non-Interventional study |
| NMRR-12-1280-14324 |
A randomized, controlled study of sarilumab and methotrexate (MTX) versus etanercept and MTX in patients with rheumatoid arthritis (RA) and an inadequate response to 4 months of treatment with adalimumab and MTX |
| NMRR-11-399-9420 |
A Long-term, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Flexible-Dose Oral Aripiprazole (OPC-14597) as Maintenance Treatment in Adolescent Patients with Schizophrenia or Child and Adolescent Patients with Bipolar I Disorder, Manic or Mixed Episode with or without Psychotic Features |
| NMRR-14-289-20398 |
A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia |
| NMRR-12-426-11014 |
A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X) |
| NMRR-12-1372-14065 |
A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase 2 Study to Assess the Efficacy and Safety of CNTO 6785 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease |
| NMRR-13-95-15050 |
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study To Evaluate The Efficacy And Safety Of Once-Daily Administration Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) In Adults With Type 2 Diabetes And Overt Nephropathy |
| NMRR-12-1249-14264 |
A Randomized Double Blind Placebo Controlled Parallelgroup Study Of The Efficacy And Safety Of Concomitant Administration Of Celecoxib And Pregabalin Compared With Celecoxib Monotherapy, In Patients With Chronic Low Back Pain Having A Neuropathic Component |
| NMRR-13-992-17879 |
UNraveling nAMD real life Clinical management and Outcome with intraVitrEal Ranibizumab injection ? A retrospective analysis (UNCOVER) |
| NMRR-11-334-9269 |
A Prospective, Randomized, Multi-centre, Placebo-controlled, Double blind, Pilot Study To Evaluate the Safety and Efficacy of BLX 1002® in Non diabetic Obese Subjects With Insulin Resistance and with Non alcoholic Fatty Liver Disease Diagnosed on Ultrasonography |
| NMRR-15-141-24026 |
An Asian, Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled 14-Week Study Of Ds-5565 In Patients With Post-Herpetic Neuralgia Followed By A 52-Week Open-Label Extension |
| NMRR-14-1494-23297 |
A cross-sectional study to investigate the pain control status in cancer patients in South East Asian countries |
| NMRR-14-702-21522 |
A Phase 3 Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin plus PA-824 plus Pyrazinamide after 4 and 6 months of Treatment in Adult Subjects with Drug-Sensitive Smear-Positive Pulmonary Tuberculosis and after 6 months of Treatment in Adult Subjects with Multi-Drug Resistant, Smear-Positive Pulmonary Tuberculosis. |
| NMRR-13-1454-18358 |
A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus |
| NMRR-12-642-12343 |
A 24-Week Randomized, Open-Label, Study to Evaluate The Safety And Efficacy of Fesoterodine in Subjects Aged 6 to 17 Years With Symptoms of Detrusor Over activity Associated with a Neurological Condition (Neurogenic Detrusor Overactivity) |
| NMRR-14-782-21691 |
Global Anticoagulant Registry in the FIELD observing treatment and outcomes in patients with treated acute Venous Thromboembolic Events in the real world |
| NMRR-15-68-23889 |
Assessment of Anatomical and Functional Outcomes in Subjects Treated with Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion (VMT/sVMA) |
| NMRR-15-991-25368 |
A two-year, randomized, double masked, multicenter, two-arm study comparing the efficacy and safety of RTH258 6 mg versus Aflibercept in subjects with neovascular age-related macular degeneration |
| NMRR-16-1051-30686 |
Safety and Efficacy with Twice Daily Brinzolamide 1% / Brimonidine 0.2% (SIMBRINZA ) as an adjunctive Therapy to Travoprost 0.004%,/ timolol 0.5% ( DUOTRAV) |
| NMRR-16-747-29183 |
Open Label Phase II/III, Multicentre Trials to assess the Efficacy, Safety, Tolerance, and Pharmacokinetics of Sofosbuvir Plus Ravidasvir in HCV (+/- HIV) Chronically Infected Adults with No Compensated Cirrhosis in Thailand and Malaysia |
| NMRR-14-1292-21778 |
PD-Improved Dialysis Efficiency with Adapted APD |
| NMRR-16-271-28984 |
A randomized, double-blind, parallel-group, multicentre study to demonstrate similar efficacy and to compare safety and immunogenicity of GP2017 and Humira® in patients with moderate to severe active rheumatoid arthritis |
| NMRR-12-1071-13841 |
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody- Positive Systemic Lupus Erythematosus Receiving Belimumab |
| NMRR-16-1527-30424 |
DNG 13 - Prospective surveillance of hospitalised dengue patients in Asia- Preparation phase of vaccine effectiveness study |
| NMRR-15-2329-28600 |
A Phase III, Randomized, Observer-Blind, Controlled, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults same as or more than 65 Years of Age. |
| NMRR-15-2466-25348 |
A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination with Methotrexate (MTX) to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Are Naïve to MTX Therapy |
| NMRR-17-391-34989 |
A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with ?Systemic Sclerosis associated Interstitial Lung Disease?(SSc-ILD). |
| NMRR-17-1265-35915 |
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects with Active Psoriatic Arthritis including those Previously Treated with Biologic Anti-TNF-alpha Agent(s) |
| NMRR-17-1264-35085 |
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects with Active Psoriatic Arthritis |
| NMRR-17-220-34137 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis |
| NMRR-16-2382-32976 |
Combined Phase 3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Chron's Disease |
| NMRR-16-2376-32972 |
Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Ulcerative Colitis |
| NMRR-16-2024-32871 |
An international non-interventional prospective cohort study to evaluate the safety of treatment with Levemir® (insulin detemir) in pregnant women with diabetes mellitus- Diabetes Pregnancy Registry |
| NMRR-17-574-34885 |
A Randomised, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered AK0529 to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Single and Multiple Dosing in Hospitalised Infants with Respiratory Syncytial Virus Infection |
| NMRR-16-1515-31768 |
A Phase IV Interventional Safety, Efficacy and Quality of Life Study of ELIGARD® in Prostate Cancer Patients in Asia (ELIGANT) |
| NMRR-17-1753-37068 |
A multicenter, Multiple-dose, Active-controlled, Double-blind, Double-dummy Study to compare the therapeutic Efficacy and safety of oral Doses of Cinacalcet Hydrochloride With Intravenous Doses of Etecalcetide (AMG 416) in Asian Hemodialysis Subjects With Secondary Hyperparathyroidism |
| NMRR-17-2557-38029 |
Randomized Controlled Multicenter Study to Evaluate the Performance of a New 2-Piece Ostomy Appliance VS Flexima® 3S in Patients with Esterostomy |
| NMRR-17-1707-36211 |
Evaluation of the Xpert Fingerstick HCV Viral Load (VL) Assay |
| NMRR-16-1514-31819 |
A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa. |
| NMRR-16-2175-32883 |
A phase II, Randomized, Double-blind, placebo-controlled dose ranging study to evaluate the safety and efficacy of M2951 in subject with Systemic Lupus Erythematous(SLE) |
| NMRR-12-181-10976 |
A Multi-centre, randomised, double-blind, placebo-controlled trial to determine thye efficiency and safety of Hepar-P capsule for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) |
| NMRR-16-1503-31818 |
A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in dialysis subjects with anaemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to recombinant human erythropoietin, following a switch from erythropoietin-stimulating agents. |
| NMRR-16-747-29183 |
Open label phase II/III, multicenter, trial to assess the efficacy, safety, tolerance, and pharmacokinetics of sofosbuvir plus ravidasvir in HCV (+/- HIV) chronically infected adults with no or compensated cirrhosis in Thailand and Malaysia |
| NMRR-17-3269-38664 |
A phase 3 Randomized, Double-blind, Placebo-controlled, multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult and Elderly Non-hospitalized PatientsWith Influenza A Infection who Are at Risk of Developing Complications. |
| NMRR-18-1266-41897 |
A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease |
| NMRR-18-2943-43568 |
Multi-center, double blind, randomised, placebo-controlled, Phase II study to investigate efficacy, safety and tolerability of BI 655130 in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to severe intensity |
| NMRR-18-2282-43132 |
Assessing the implementation of decentralized HCV testing at Primary Health Care facilities in Malaysia |
| NMRR-18-2961-44888 |
A Phase 3, Randomized, Double-Blind, Study Comparing Raisankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who have a history of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy |
| NMRR-18-2552-44108 |
A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses of JNJ-53718678 in Children ≥28 Days and ≤3 Years of Age With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus Infection |
| NMRR-19-579-46537 |
An Eighteen-month, Two-arm, Randomized, Double-masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Central Retinal Vein Occlusion (RAVEN) |
| NMRR-18-544-40614 |
Clinical Validation of the Venn Ovarian Cancer Liquid Biopsy: VOCAL Study |
| NMRR-19-1916-48399 |
A 64-week, two-arm, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of brolucizumab 6mg compared to aflibercept 2mg in a treat-to-control regimen in patients with neovascular age related macular degeneration (TALON) |
| NMRR-19-1382-47113 |
A Phase 2B, Multicenter, Double-blind, Randomized Study to Investigate the Efficacy and Safety of Different Combination Regimens Including JNJ-73763989 And/Or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection. |
| NMRR-18-3755-45486 |
An international observational study in emerging markets to estimates the burden of illness in adult atopic dermatitis patients |
| NMRR-19-2135-48361 |
A 52-weeks, phase 3, Multicentre, randomised, double-blind, efficacy and safety study comparing GSK3196165 with placebo and with tofaticinid, in combination with methotrexate in participants with moderately to severely active rheumatoid arthritis who have an inadequate response to methotrexate. |
| NMRR-19-3448-50473 |
A randomized, double-blind, placebo-controlled, parallel group, phase III multicenter study of intravenous secukinumab to compare efficacy at 16weeks with placebo and to assess safety and tolerability up to 52 weeks in subjects with Axial Spondyloarthritis comprising patients with active Ankylosing Spondylitis and non-radiographic axial spondyloarthritis |
| NMRR-19-3581-50303 |
A randomized, double-blind, placebo-controlled, parallel group, phase III multicenter study of intravenous secukinumab to compare efficacy at 16weeks with placebo and to assess safety and tolerability up to 52 weeks in subjects with active Psoriatic Arthritis |
| NMRR-20-756-54416 |
Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218 Alone or in Combination with Pegylated Interferon Alpha-2a |
| NMRR-20-2327-56660 |
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the efficacy and safety of rilematovir in infants and children (≥28 Days and ≤5 Years of Age) and subsequently in neonates ( < 28 days of age), hospitalized with acute respiratory tract infection due to respiratory syncytial virus ( RSV) |
| NMRR-20-2331-56517 |
A 56-week phase IIIb/IV, open-label, one-arm extension study to assess the efficacy and safety of brolucizumab 6 mg in a Treat-to-Control regimen with maximum treatment intervals up to 20 weeks for the treatment of patients with neovascular age-related macular degeneration who have completed the CRTH258A2303 (TALON) study. |
| NMRR-21-1377-60851 |
An Interventional Efficacy And Safety, Phase 2/3, Double-Blind, 2-Arm Study To Investigate Orally Administered Pf-07321332/Ritonavir Compared With Placebo In Nonhospitalized Symptomatic Adult Participants With Covid-19 Who Are At Low Risk Of Progressing To Severe Illness
|
| NMRR-21-1376-60856 |
A Phase 2/3, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study To Evaluate The Safety And Efficacy Of 2 Regimens Of Orally Administered Pf-07321332/Ritonavir In Preventing Symptomatic Sars-Cov-2 Infection In Adult Household Contacts Ofan Individual With Symptomatic Covid-1
|
| NMRR-20-2846-57865 |
Randomised, double-blind (within dose groups), placebo-controlled and parallel group trial to investigate the effects of different doses of oral BI 685509 given over 20 weeks on UACR reduction in patients with diabetic kidney disease |
| NMRR-20-2854-57866 |
Randomised, double-blind (within dose groups), placebo-controlled and parallel group trial to investigate the effects of different doses of oral BI 685509 given over 20 weeks on UACR reduction in patients with non-diabetic kidney disease |
| NMRR-21-615-58768 |
A Phase 2 Study to evaluate the Safety, Tolerability, and Efficacy of VIR-2218 + VIR3434 in Subjects with Chronic HepB Virus |
| NMRR-21-1255-60315 |
A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in participants with Active Psoriatic Arthritis who has an Inadequate Response and/or Intolerance to one Prior Anti-Tumor Necrosis Factor Agent (CNTO1959PSA3005) |
| NMRR-21-1365-60297 |
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Preliminary Efficacy of SIR1-365 in Patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome |
| NMRR-20-2247-56762 |
Multicenter, double-blind, parallel-group, randomised, 48 weeks, dose-ranging, placebo-controlled phase II trial to evaluate efficacy, safety and tolerability of multiple subcutaneous (s.c.) doses of BI 456906 in patients with non-alcoholic steatohepatitis (NASH) and fibrosis |
| NMRR-21-1863-61541 |
Randomised, double-blind, placebo-controlled and parallel dose group trial to investigate efficacy and safety of multiple dose of oral BI 690517 over 14 weeks, alone and in combination with empagliflozin, in patients with diabetic and non-diabetic chronic kidney disease |
| NMRR-21-1903-61142 |
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the efficacy and safety of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis |
| NMRR-21-02236-SHK |
Acute Respiratory Infections Global Outpatient Study (ARGOS). |
| NMMR -22-01132-8KT |
Immunogenicity, Efficacy and Safety of Inhaled (IH) viral vectored vaccine (Convidecia, CanSino) as second booster dose against emerging Variants of Concern (VOC) of SARS-CoV-2 to prevent breakthrough infections. A randomized observer-blind controlled trial |
| NMRR-22-00257-IPJ |
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Trial Assessing the Efficacy and Safety of Two Dose Regimens of JNJ-64281802 for the Prevention of Dengue Infection. |
| NMRR-22-02522-BO4 |
A Phase 3, International, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants with CKD and Hyperkalaemia or at Risk of Hyperkalaemia |
| NMRR-23-00470-IOG |
An International, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis with Recurrent Hyperkalemia (DIALIZE-Outcomes) |
| NMRR-23-01230-BXV/S1 |
A multicenter study of secukinumab, with a randomized double-blind, placebo-controlled withdrawal-retreatment period, to evaluate maintenance of response in participants with non-radiographic axial spondyloarthritis who achieved remission |
